Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EPS (Weighted Average and Diluted) (2021 - 2025)

Bolt Biotherapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$3.72 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 830.0% year-over-year to -$3.72; the TTM value through Sep 2025 reached $9.14, up 174.49%, while the annual FY2024 figure was -$1.65, 9.84% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$3.72 at Bolt Biotherapeutics, up from -$9.93 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $23.08 in Q4 2024 and bottomed at -$11.12 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.53 (2022), against an average of -$0.48.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 5010.64% in 2024 against a maximum downside of 2216.67% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.73 in 2021, then rose by 27.4% to -$0.53 in 2022, then increased by 11.32% to -$0.47 in 2023, then skyrocketed by 5010.64% to $23.08 in 2024, then tumbled by 116.12% to -$3.72 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's EPS (Weighted Average and Diluted) are -$3.72 (Q3 2025), -$9.93 (Q2 2025), and -$0.29 (Q1 2025).